Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 1/20 | 0.49 |
| ▸ | TLR2 | O60603 | 1/20 | 0.46 |
| ▸ | GHSR | Q92847 | 1/20 | 0.46 |
| ▸ | GNPAT | O15228 | 1/20 | 0.46 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.45 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.45 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.45 |
| ▸ | FURIN | P09958 | 1/20 | 0.45 |
| ▸ | MMP1 | P03956 | 2/20 | 0.45 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.45 |
| ▸ | MMP3 | P08254 | 1/20 | 0.45 |
| ▸ | FCER2 | P06734 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29448214 | 0.84 | CPB2 (0.53) | ANPEPMMP2TLR2GNPATERAP2 | |
| SCHEMBL2547160 | 0.82 | ANPEP (0.51) | ANPEPMMP2TLR2GHSRERAP2 | |
| SCHEMBL22845647 | 0.82 | GHSR (0.55) | GHSRGNPATERAP2LNPEPERAP1 | |
| SCHEMBL15948101 | 0.82 | GNPAT (0.54) | ANPEPMMP2GHSRGNPATERAP2 | |
| SCHEMBL18499711 | 0.82 | GHSR (0.55) | GHSRGNPATERAP2LNPEPERAP1 | |
| SCHEMBL22695740 | 0.82 | GNPAT (0.54) | ANPEPMMP2GHSRGNPATERAP2 | |
| SCHEMBL6431108 | 0.81 | MMP2 (0.56) | MMP2GHSRERAP2LNPEPERAP1 | |
| SCHEMBL22695988 | 0.81 | MMP2 (0.56) | ANPEPMMP2GNPATERAP2LNPEP | |
| SCHEMBL30688828 | 0.81 | MMP2 (0.56) | MMP2GHSRERAP2LNPEPERAP1 | |
| SCHEMBL16856622 | 0.81 | MMP2 (0.56) | ANPEPMMP2GNPATERAP2LNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215985-A1 | DIFFERENTIALLY PROTECTED ORTHOGONAL LANTHIONINE TECHNOLOGY | ORAGENICS, INC. | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215985-A1 | DIFFERENTIALLY PROTECTED ORTHOGONAL LANTHIONINE TECHNOLOGY | VIP, LGMN, LNPEP | ANPEP 47/4885MMP2 3155/4885TLR2 1181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.